埃博拉病毒 z-bio 2021-06-11 643

　　The best international academic journal Science published online a research paper by Einstein Medical College researcher Kartik Chandran. This study shows that bi-directional antibodies can combat unique antigen escape mechanisms such as Ebola.

　　This is an important step in the development of extensive protection measures against the Ebola virus. There is still an urgent need for such treatment. Filaviruses, including Ebola, have abnormal ways to enter host cells. They enter the cell through small transport vesicles (or endosomes), where they interact with a host cell called PC1. The receptor interacts to remove the mask. In fact, this two-step route has a barrier effect. It allows the virus to hide in the immune system and interfere with the effectiveness of antiviral treatments. In order to find a way to resist this evolving antigenic mechanism, Anna Wec et al. designed a bispecific antibody that can first bind to and rely on a specific glycoprotein (GP) outside the virus. (very much). It can then bind to PC1 in the endosome (just like a Trojan horse), prevent GP from binding to PC1, and release the Ebola virus into the host cell. In human cell lines, Wec et al. confirmed that these antibodies can neutralize the activity of all known Ebola viruses and demonstrated their potential in broad-spectrum anti-Ebola virus therapy. They also evaluated the efficacy of these antibodies in a mouse model and found that 70 mice survived 2 days after being infected with multiple lethal Ebola viruses compared to untreated controls. According to the authors, the bispecific antibody system has been shown to be resistant to other viral pathogens known to hijack intracellular receptors, such as Lassa virus.